Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
NCT01891643 · Bristol-Myers Squibb · PHASE3 · terminated · last registry update 2021-07-01 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient enrollment” | Open Targets' class: insufficient enrollment | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLAMF7 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-04Also stopped (withdrawn): Tulane University School of Medicine, Elotuzumab, Selinexor, and Dexamethasone (ESd) (NCT05170789)
- 2022-04-14Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Elotuzumab + Lenalidomide (NCT03411031)
- 2022-03-31Also stopped (terminated): Oncotherapeutics, Elotuzumab + Pomalidomide (NCT03104270)
- 2021-10-27Results posted on the registry: SWOG Cancer Research Network, Bortezomib + Dexamethasone (NCT01668719)
- 2021-08-31Phase 3 first posted: European Myeloma Network B.V., Selinexor + Elotuzumab (NCT05028348)
- 2021-08-23Also stopped (withdrawn): Natalie Callendar, Elotuzumab + Pomalidomide (NCT04584307)
- 2020-10-22Results posted on the registry: Bristol-Myers Squibb, Lenalidomide + Dexamethasone (NCT01335399)
- 2020-08-06Results posted on the registry: Bristol-Myers Squibb, Elotuzumab + Pomalidomide (NCT02612779)
- 2020-07-10Also stopped (withdrawn): University of Arkansas, Elotuzumab + Melphalan (NCT03003728)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision